Therapy built on tumour-infiltrating lymphocytes is now being prepared for at least 20 people in the United States with advanced melanoma. Therapy built on tumour-infiltrating lymphocytes is now being prepared for at least 20 people in the United States with advanced melanoma.
Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves. Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves.